Pyelonephritis, a bacterial infection of the kidney, is treated primarily with antibiotics, and most otherwise healthy people can complete the entire course at home with oral medications. The standard regimen lasts about a week for many patients, though the exact drug, dose, and duration depend on factors like local resistance patterns, pregnancy, the presence of urinary obstruction, and how sick someone is at diagnosis. Getting the details right matters because undertreated pyelonephritis can scar the kidney or progress to life-threatening sepsis, while overtreated cases pile on unnecessary drug exposure and side effects.
Who Can Be Treated at Home and Who Needs the Hospital
The first decision a clinician faces is whether you can safely go home with a prescription or whether you need intravenous antibiotics in the hospital. Most young, otherwise healthy adults with uncomplicated pyelonephritis can be managed as outpatients, provided they can keep fluids and pills down. Hospital admission becomes more likely when certain risk factors stack up. A risk-stratification study from emergency departments found that age 65 or older, rigors (shaking chills), elevated inflammatory markers, impaired kidney function, and low albumin each independently raised the odds of needing admission; patients who accumulated several of these factors had admission rates above 80 percent.1PubMed. A risk stratification model of acute pyelonephritis to indicate hospital admission from the ED
Practical reasons also tip the scale toward hospitalization. If you are vomiting too much to absorb oral medications, if you are pregnant, if you have an obstruction like a kidney stone blocking the ureter, or if your vital signs suggest early sepsis, outpatient therapy is not safe. People with diabetes, immunosuppression, or structural urinary tract abnormalities also tend to be admitted because their infections are more likely to become complicated.
Choosing Outpatient Antibiotics
For uncomplicated pyelonephritis treated at home, fluoroquinolones like ciprofloxacin have traditionally been the first-line oral option. A landmark randomized trial comparing seven days of ciprofloxacin against fourteen days of trimethoprim-sulfamethoxazole (TMP-SMX) found bacteriologic cure rates of 99 percent with ciprofloxacin versus 89 percent with TMP-SMX, driven largely by resistance: 18 percent of the E. coli isolates were resistant to TMP-SMX while none were resistant to ciprofloxacin at the time of the study.2PubMed. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial That trial cemented fluoroquinolones as the go-to choice for years.
The picture has shifted somewhat since then. Fluoroquinolone resistance has risen globally, and regulatory agencies have flagged serious side effects (tendon damage, nerve problems, aortic dissection risk in certain populations), so clinicians now weigh those harms more carefully. TMP-SMX remains an option when susceptibility testing confirms the bug is sensitive to it. A retrospective comparison found that when both drugs were given for seven days, the likelihood of a recurrent infection within 30 days was statistically similar between TMP-SMX and ciprofloxacin.3PubMed Central. A Seven-Day Course of Trimethoprim-Sulfamethoxazole May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis In practice, the choice between them hinges on what the urine culture shows: if TMP-SMX will work, many clinicians now prefer it to spare fluoroquinolones for situations where no alternative exists.
Third-generation oral cephalosporins like cefpodoxime or cefdinir are another option, though their tissue penetration in the kidney is not as strong as fluoroquinolones or TMP-SMX, and clinical data for them in pyelonephritis are thinner. They tend to appear as fallback choices when neither a fluoroquinolone nor TMP-SMX is suitable.
How Long the Antibiotic Course Lasts
Shorter courses are gaining ground. A 2025 living systematic review and meta-analysis that pooled twelve randomized trials found no meaningful difference in clinical success between five-to-seven-day regimens and ten-to-fourteen-day regimens. That held true across subgroups, including men (who historically received longer courses) and patients treated with non-quinolone antibiotics.4PubMed. Short vs. long antibiotic treatment for pyelonephritis and complicated urinary tract infections: a living systematic review and meta-analysis of randomized controlled trials For fluoroquinolones, a seven-day course is now widely accepted as standard. When TMP-SMX is used, some guidelines still suggest ten to fourteen days because the older comparative trial tested it at that longer duration, but the meta-analysis data suggest seven days is probably sufficient for most patients regardless of the specific drug.
The push to shorten courses is part of a broader stewardship effort. Every additional day of antibiotics increases the chance of side effects, disrupts gut flora, and raises the risk of selecting for resistant organisms. When the evidence shows that a shorter course works equally well, there is little reason to keep dosing.
Intravenous Treatment and the Switch to Oral
If you are sick enough to be admitted, treatment typically starts with intravenous antibiotics, often a broad-spectrum cephalosporin, a fluoroquinolone, or a carbapenem depending on local resistance and illness severity. The encouraging news is that you probably will not need to stay on an IV for long. A systematic review of randomized controlled trials found that switching from intravenous to oral antibiotics early, sometimes after just two or three days, produced outcomes identical to completing a full intravenous course. The reviewers concluded that hospital IV duration could potentially be shortened by four to eleven days without compromising results, in both adults and children.5PubMed. Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled trials
In practice, the typical approach is to give IV antibiotics until the fever breaks and symptoms improve, usually within 48 to 72 hours, then transition to an oral agent guided by culture results to finish the remaining days at home. This approach shortens hospital stays, reduces IV-line complications, and cuts costs without sacrificing cure rates.
Culture Results and De-Escalation
A urine culture taken before antibiotics are started is the single most important tool for guiding therapy. Initial treatment is empiric, meaning clinicians pick a broad-spectrum drug based on what the likely pathogen is and what resistance patterns look like locally. Once the lab identifies the specific organism and which antibiotics it is sensitive to, the regimen should be narrowed. Updated guidelines from the Infectious Diseases Society of America recommend switching to the most targeted effective antibiotic as soon as culture results are available, rather than continuing a broad-spectrum agent for the entire course.6Clinical Infectious Diseases. IDSA 2025 Guideline Update on Complicated Urinary Tract Infections – Section: Selection of Definitive Antibiotic Therapy for Complicated UTI
In reality, de-escalation happens less consistently than it should. One hospital analysis found that about two-thirds of patients with cystitis or pyelonephritis had their antibiotics narrowed in response to susceptibility results, but roughly five percent were identified as candidates for de-escalation that never occurred.7Open Forum Infectious Diseases. Incidence of Antibiotic De-escalation in Hospitalized Internal Medicine Patients Diagnosed With Cystitis or Pyelonephritis That gap matters because continuing unnecessarily broad antibiotics promotes resistance and increases the risk of drug-related side effects like Clostridioides difficile colitis.
When Obstruction Complicates Things
Pyelonephritis in the presence of a urinary tract obstruction, most commonly a kidney stone wedged in the ureter, is a different animal. Antibiotics alone cannot clear an infection if infected urine is trapped behind a blockage. These patients need emergency drainage to decompress the kidney, and they usually need it fast.
Two main drainage methods exist: a percutaneous nephrostomy tube (a catheter placed through the back directly into the kidney under imaging guidance) or a ureteral stent inserted retrograde through the bladder. A single-center series found both approaches to be effective and safe, noting that percutaneous nephrostomy under local anesthesia was useful for quickly controlling fever and allowing earlier definitive surgical treatment of the underlying stone.8Archivio Italiano di Urologia e Andrologia. Emergency treatment of obstructive pyelonephritis: A single center series A prospective randomized trial in patients with ureteral stones and signs of systemic infection similarly found no significant difference between the two drainage techniques in hospital stay or time for fever to normalize, though the nephrostomy group trended toward faster defervescence.9PubMed Central. Emergency decompression for patients with ureteral stones and SIRS: a prospective randomized clinical study The choice between them often comes down to the patient’s anatomy, the surgeon’s expertise, and how unstable the patient is.
Emphysematous Pyelonephritis
Emphysematous pyelonephritis (EPN) is a rare but potentially lethal form of the infection in which gas-forming organisms destroy kidney tissue. It occurs almost exclusively in people with uncontrolled diabetes or an obstructed urinary tract. Decades ago the standard treatment was emergency removal of the kidney, but outcomes have shifted dramatically. A systematic review found that medical management alone carried roughly 50 percent mortality, emergency nephrectomy brought that down to about 25 percent, and percutaneous drainage combined with antibiotics dropped it further to around 13.5 percent.10PubMed. Is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review
Current practice favors starting with broad-spectrum IV antibiotics (usually a third- or fourth-generation cephalosporin or a carbapenem), aggressive fluid resuscitation, and percutaneous drainage if there is a fluid or gas collection amenable to it.11PubMed Central. Emphysematous pyelonephritis: classification, management, and prognosis Nephrectomy is reserved for patients who fail to respond.12Journal of Clinical Imaging Science. Percutaneous drainage for non-operative management of emphysematous pyelonephritis: Clinical characteristics and predictors of success CT imaging helps predict who will respond to conservative treatment: absence of hydronephrosis and smaller volumes of gas in the kidney tissue are associated with better outcomes from non-surgical management.13Egyptian Journal of Radiology and Nuclear Medicine. Diagnostic performance of pre-management computed tomography findings as a predictor of conservative treatment success in patients with emphysematous pyelonephritis
Treatment During Pregnancy
Pyelonephritis in pregnancy is always treated as a serious condition. Pregnant patients are routinely hospitalized, at least initially, because the infection raises the risk of preterm labor, low birth weight, and maternal sepsis. Antibiotic options are more limited because fluoroquinolones and TMP-SMX carry fetal risks and are generally avoided.
A review of international guidelines found that most recommend starting with an intravenous third-generation cephalosporin like ceftriaxone, or a second-generation cephalosporin like cefuroxime. If the patient shows signs of sepsis, adding an aminoglycoside such as gentamicin is a common step. Combination regimens of ampicillin plus gentamicin are also used in some settings.14PubMed Central. Which Antibiotic for Urinary Tract Infections in Pregnancy? A Literature Review of International Guidelines – Section: 3.4. Antibiotics in APN Head-to-head data comparing different regimens in pregnant women are thin, so the choice often comes down to local resistance patterns and what is safest for the developing fetus.15PubMed. Pyelonephritis in pregnancy: an update on treatment options for optimal outcomes
After the acute IV phase, pregnant patients are typically stepped down to an oral cephalosporin to complete the course. Many clinicians then prescribe low-dose antibiotic suppression for the remainder of the pregnancy because the physiological changes that dilate the ureters during pregnancy make recurrence common.
Pyelonephritis in Children
For years, the default in pediatric pyelonephritis was to hospitalize the child and give a full course of intravenous antibiotics. That approach has softened considerably. A Cochrane review of pediatric trials concluded that children with acute pyelonephritis can be treated effectively with oral antibiotics like cefixime or with short IV courses of two to four days followed by oral therapy, though the reviewers noted that more data were needed to confirm this in very young infants.16Cochrane Database of Systematic Reviews. Antibiotics for acute pyelonephritis in children
A large multicenter trial comparing ten days of oral cefixime against three days of IV ceftriaxone followed by oral cefixime found no significant difference in renal scarring at one year, with rates of about 14 percent in the oral-first group and 18 percent in the IV-first group.17BMJ. Antibiotic treatment for pyelonephritis in children: multicentre randomised controlled non-inferiority trial A separate study specifically examining short versus prolonged antibiotic courses in children with pyelonephritis found treatment failure rates of about 11 percent versus 9 percent, a difference that was not statistically significant.18JAMA Network Open. Comparative Effectiveness of Antibiotic Treatment Duration in Children With Pyelonephritis
The main concern in pediatric cases is kidney scarring, because damaged kidneys in a growing child can lead to hypertension or impaired renal function later in life. Data here are somewhat contradictory. An Italian study found that the risk of scarring remained constant at about 31 percent regardless of whether antibiotics were started within one day or after five or more days of fever.19PubMed. Early treatment of acute pyelonephritis in children fails to reduce renal scarring: data from the Italian Renal Infection Study Trials However, a different study found that a total fever duration exceeding 72 hours before treatment was the single strongest predictor of scarring on follow-up imaging.20PubMed. Delayed treatment of the first febrile urinary tract infection in early childhood increased the risk of renal scarring The practical takeaway for parents is straightforward: a febrile child with urinary symptoms should see a doctor promptly, but the window is measured in days rather than hours, and there is no reason to panic over a few hours of delay.
Dealing With Resistant Organisms
Antibiotic resistance is the biggest complication in modern pyelonephritis treatment. Extended-spectrum beta-lactamase (ESBL) producing bacteria are increasingly common and are resistant to most standard oral antibiotics, including cephalosporins and often fluoroquinolones. The traditional IV workhorse for ESBL infections has been a carbapenem like meropenem, but carbapenems are considered “last resort” antibiotics, and overuse drives further resistance.
Efforts to find carbapenem-sparing alternatives are active. A retrospective study comparing cefoperazone-sulbactam with meropenem for ESBL-producing pyelonephritis found comparable clinical and microbiological outcomes, suggesting that the combination antibiotic may be a viable option for less critically ill patients.21Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University. Carbapenem-Sparing Therapy of ESBL- Enterobacterales Pyelonephritis: A Retrospective Comparison of Cefoperazone-Sulbactam and Meropenem This is still an evolving area, and the right choice depends heavily on what the culture and sensitivity results show. The broader lesson is that empiric therapy should be followed up with culture-guided adjustment, especially in regions where ESBL rates are high.
Dose Adjustment in Kidney Impairment
Pyelonephritis itself can temporarily damage kidney function, and many patients present with at least mildly elevated creatinine. This creates a tricky pharmacologic problem: standard dosing guidelines for many antibiotics call for dose reductions when kidney function drops, but those reductions were designed for patients with chronic, stable kidney disease. In acute kidney injury, the reduced function is often transient, and cutting the dose too aggressively can leave antibiotic levels too low to clear the infection. An analysis in Clinical Infectious Diseases flagged this issue explicitly, noting that several newer antibiotics carry warnings of reduced clinical response in patients with moderately impaired kidney function, likely because dose reductions made in the setting of acute injury were inappropriate.22Clinical Infectious Diseases. Renal Dosing of Antibiotics: Are We Jumping the Gun? For patients and for clinicians, the point is that a creatinine spike during acute pyelonephritis does not always mean the antibiotic dose should be slashed. Clinical judgment and sometimes drug-level monitoring are needed.
Preventing Recurrence
After a first episode of pyelonephritis, many people understandably want to know how to avoid a second one. The standard strategy has been low-dose antibiotic prophylaxis, taken nightly for months, but interest in non-antibiotic alternatives is growing. A meta-analysis pooling studies of various non-antibiotic interventions (including cranberry products, D-mannose, vaginal estrogen in postmenopausal women, and probiotics) found that these approaches actually reduced recurrent urinary tract infections more than antibiotic prophylaxis, with a pooled relative risk of 0.75.23Brawijaya Journal of Urology. A Systematic Review and Meta-Analysis of Non-Antibiotic Agents in Comparison to Antibiotic Therapies for Prevention of Recurrent Urinary Tract Infection That result is promising, though the studies it pooled were heterogeneous and the comparison is with antibiotics, not placebo, so the finding is more about stewardship, showing that non-antibiotic options can be competitive, rather than proving any single supplement is a cure-all.
In children specifically, a trial of probiotic prophylaxis in infants who had recovered from pyelonephritis found a recurrence rate of about 8 percent with probiotics compared to 21 percent with no prophylaxis, and the probiotic group was statistically similar to the group receiving antibiotic prophylaxis.24PubMed. Probiotics prophylaxis in pyelonephritis infants with normal urinary tracts These results are encouraging but still preliminary. For adults, the behavioral basics remain important: adequate hydration, prompt treatment of lower urinary tract infections before they ascend, and in women, addressing risk factors like frequent sexual activity or spermicide use.
Fungal Pyelonephritis
Not all pyelonephritis is bacterial. In immunocompromised patients, those with poorly controlled diabetes, or people with indwelling urinary catheters, fungal organisms can infect the kidney. Candida species are the most common culprits and are a growing concern in hospital settings.25PubMed Central. Urinary tract infections and Candida albicans Rarer molds like Aspergillus and Mucor have also been reported; a case series described four patients with these unusual infections, three of whom had diabetes. Management ranged from percutaneous nephrostomy to nephrectomy, and all four patients responded to individualized treatment combining antifungal drugs with procedural intervention.26PubMed Central. Beyond Candida: A clinical insight into rare fungal pyelonephritis in urological practice Fungal pyelonephritis does not respond to standard antibacterial antibiotics, which means it is often missed initially. Clinicians should suspect it when a patient with the right risk factors fails to improve on conventional therapy, and urine cultures should specifically request fungal screening in those cases.
Hospital-at-Home Programs
An emerging model that blurs the line between outpatient and inpatient care is the hospital-at-home program, where patients who would traditionally be admitted receive IV antibiotics, fluids, and monitoring in their own residence. A multi-site cohort treated in such a program found that 30-day readmission after pyelonephritis was driven by underlying genitourinary complexity (structural abnormalities, recurrent stones, prior urologic surgery) rather than by how sick the patient was at the time of treatment or by treatment-related factors.27The American Journal of Medicine. Patient Characteristics and Clinical Outcomes of Acute Pyelonephritis Treated in Mayo Clinic’s Hospital-at-Home Program For patients with straightforward anatomy and infections that need IV therapy but not intensive monitoring, this kind of program can be a comfortable middle ground, though availability is still limited to certain health systems.